

## CORPORATE PROFILE

Sino Biopharmaceutical Limited (the “Company”), together with its subsidiaries and a jointly-controlled entity (the “Group”) (Fig. 1.1), is an integrated pharmaceutical enterprise. The Group researches and develops, manufactures and markets a vast array of biopharmaceuticals, modernised Chinese medicines and chemical medicines by applying advanced biotechnology and modernised Chinese medicinal technology.

The Group focuses on the development and commercialisation of products in two core therapeutic categories: cardio cerebral diseases and hepatitis, and also actively develops medicines for treathy oncology, analgesia, respiratory system, diabetes and digestive system diseases to meet the increase demands of the market, medical practitioners and patients. Principal products include:

Cardio-cerebral medicines : Kaishi (Alprostadil) injections and Spring (Purarin) injections

Hepatitis medicines : Ganlixin (Diammonium Glycyrrhizinate) injections and capsules, Tianqingfuxin (Marine) injections and capsules

Oncology medicines : Tianqingyitai (Zolebronnate Acid) injections

Analgesic medicines : Kaifen (Flurbiprofen Axetil) injections

Products with great potentials include:

Hepatitis medicines : Tianqingganmei (Magnesium Isoglycyrrhizinate) injections, Tianqingganping (Diammonium Glycyrrhizinate) enteric capsules, Carnet (Foscarnet Sodium) injections;

Cardio-cerebral medicines : Tianqinggan (Glycerin and Fructose) injections

Oncology medicines : Renyi (Pamidronate Disodium) injections

Respiratory medicines: : Tianqingzhengshu (Loratadine) tablets

The Group’s medicines have received Good Manufacturing Practices (“GMP”) certification issued by the State Food and Drug Administration (“SFDA”) of the People’s Republic of China (“PRC”). They are: large volume injections; small volume injections; Powder injections; tablets; capsules; powdered medicines; granulated medicines; and PVC-free soft bags for intravenous injections.

The Group’s principal subsidiary – Jiangsu Chia Tai – Tianqing Pharmaceutical Co. Ltd. (“JCTT”) and a jointly-controlled entity, Beijing Tide Pharmaceutical Co. Ltd. (“Beijing Tide”) have been designated as “High and New Technology Enterprise” and “Advanced Technology Enterprise”. Beijing Chia Tai Green Continent Pharmaceutical Co. Ltd. (“CTGC”) has been designated as “High and New Technology Enterprise”.

The research department of JCTT was recognized as the “Postdoctoral Research & Development Institute” by the PRC’s Ministry of Personnel. It is the country’s unique “New Hepatitis Pharmaceutical Engineering Research and Technology Centre” designated from Science and Technology Committee of Jiangsu Provincial.

Website: <http://www.sinobiopharm.com>

Stock code: 1177

### GROUP STRUCTURE

Fig. 1.1

